Update 02 March 2022:
NuCana’s NuTide:121 Trial for those with advanced biliary tract cancer is stopped.
Independent data monitoring committee recommended study be discontinued following futility assessment conducted at first interim analysis. To see NuCana’s press release, go to: https://ir.nucana.com/news-releases/news-release-details/nucana-announces-update-phase-3-biliary-tract-cancer-study
NuTide:121 will compare NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients with Advanced Biliary Tract Cancer.
The study opened to recruitment in December 2019 and will enrol up to 828 patients globally. There will be a number of UK sites be participating.
(The NUC-1031 Plus Cisplatin combination was developed through the UK ABC-08 study)
NuTide:121 is open and recruiting at the following sites:
|Palmer, Daniel||The Clatterbridge Cancer Centre|
|Valle, Juan||The Christie|
|Ross, Paul||Guy’s Hospital|
|Braconi, Chiara||Beatson West of Scotland Cancer Centre|
|Christie, Alan||Western General Hospital|
|Rees, Charlotte||Southampton General Hospital – due to open at this site during 2020|